Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2150-2164

  Baghy, Kornélia ^a   Horváth, Zsolt ^a   Regos, Eszter ^a   Kiss, Katalin ^a   Schaff, Zsuzsa ^a   Iozzo, Renato V ^b   Kovalszky, Ilona ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

carcinogenesis; decorin; liver cancer; platelet derived growth factor receptor alpha; proteoglycan

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DECORIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; THIOACETAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FIBROBLAST; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DECORIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOCYTES; HUMANS; LIGANDS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; THIOACETAMIDE; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84877700624     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12215     Document Type: Article

References (83)

1. Ferdous Z, Wei VM, Iozzo R, Hook M, &, Grande-Allen KJ, (2007) Decorin-transforming growth factor- interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 282, 35887-35898. (Pubitemid 350277129)
2. Hocking AM, Shinomura T, &, McQuillan DJ, (1998) Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17, 1-19. (Pubitemid 28206020)
3. Baghy K, Dezso K, Laszlo V, Fullar A, Peterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, &, Kovalszky I, (2011) Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91, 439-451.
4. Dudas J, Kovalszky I, Gallai M, Nagy JO, Schaff Z, Knittel T, Mehde M, Neubauer K, Szalay F, &, Ramadori G, (2001) Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am J Clin Pathol 115, 725-735. (Pubitemid 33051540)
5. Yamaguchi Y, Mann DM, &, Ruoslahti E, (1990) Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346, 281-284.
6. Baghy K, Iozzo RV, &, Kovalszky I, (2012) Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 60, 262-268.
7. Schaefer L, (2011) Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 22, 1200-1207.
8. Iozzo RV, (1997) The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32, 141-174. (Pubitemid 27209329)
9. Iozzo RV, (1999) The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 274, 18843-18846. (Pubitemid 29314072)
10. Santra M, Eichstetter I, &, Iozzo RV, (2000) An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275, 35153-35161.
11. Iozzo RV, Moscatello DK, McQuillan DJ, &, Eichstetter I, (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274, 4489-4492.
12. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, &, Iozzo RV, (2005) Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 280, 32468-32479. (Pubitemid 41361859)
13. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, &, Iozzo RV, (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743-754.
14. Schonherr E, Sunderkotter C, Iozzo RV, &, Schaefer L, (2005) Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280, 15767-15772. (Pubitemid 40616696)
15. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, Gomella LG, Owens RC, &, Morrione A, (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286, 34712-34721.
16. Khan GA, Girish GV, Lala N, Di Guglielmo GM, &, Lala PK, (2011) Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol Endocrinol 25, 1431-1443.
17. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, &, Iozzo RV, (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 4765-4777. (Pubitemid 34879452)
18. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, &, Iozzo RV, (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149-157. (Pubitemid 27311253)
19. Iozzo RV, (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 73, 157-160.
20. Neill T, Schaefer L, &, Iozzo RV, (2012) Decorin: a guardian from the matrix. Am J Pathol 181, 380-387.
21. Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, Evans B, Schaefer L, Peiper SC, Wang ZX, et al,. (2012) Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS ONE 7, e45559.
22. Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, Wang YL, &, Dai GH, (2011) Coexpression of PDGFR-alpha. PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers 26, 108-116.
23. Furuse J, (2008) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2, 779-788.
24. Pang RW, &, Poon RT, (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 (Suppl 1), 30-44. (Pubitemid 350256663)
25. Oseini AM, &, Roberts LR, (2009) PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 13, 443-454.
26. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, &, Monga SP, (2007) Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6, 1932-1941. (Pubitemid 47052483)
27. Shangguan JY, Dou KF, Li X, Hu XJ, Zhang FQ, Yong ZS, &, Ti ZY, (2009) Effects and mechanism of decorin on the proliferation of HuH7 hepatoma carcinoma cells in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25, 780-782.
28. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, et al,. (2002) Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 14, 382-387. (Pubitemid 41582962)
29. Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe M, &, Sato C, (2001) Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br J Cancer 85, 228-234. (Pubitemid 32695744)
30. Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R, Eskandarian MR, Smeets M, Butany J, Pasterkamp G, et al,. (2003) Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am J Pathol 163, 869-878. (Pubitemid 37040123)
31. Becker FF, (1983) Thioacetamide hepatocarcinogenesis. J Natl Cancer Inst 71, 553-558. (Pubitemid 13012133)
32. Camus-Randon AM, Raffalli F, Bereziat JC, McGregor D, Konstandi M, &, Lang MA, (1996) Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol Appl Pharmacol 138, 140-148. (Pubitemid 26159604)
33. Daley WP, Peters SB, &, Larsen M, (2008) Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 121, 255-264. (Pubitemid 351356696)
34. Jarvelainen H, Sainio A, Koulu M, Wight TN, &, Penttinen R, (2009) Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 61, 198-223.
35. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, &, Mongiat M, (2008) Extracellular matrix: a matter of life and death. Connect Tissue Res 49, 203-206.
36. Rozario T, &, DeSimone DW, (2010) The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol 341, 126-140.
37. Hynes RO, (2009) The extracellular matrix: not just pretty fibrils. Science 326, 1216-1219.
38. Hielscher AC, Qiu C, &, Gerecht S, (2012) Breast cancer cell-derived matrix supports vascular morphogenesis. Am J Physiol Cell Physiol 302, C1243-C1256.
39. Ferdous Z, Peterson SB, Tseng H, Anderson DK, Iozzo RV, &, Grande-Allen KJ, (2010) A role for decorin in controlling proliferation, adhesion, and migration of murine embryonic fibroblasts. J Biomed Mater Res A 93, 419-428.
40. Iozzo RV, &, Schaefer L, (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
41. Seidler DG, &, Dreier R, (2008) Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function? IUBMB Life 60, 729-733.
42. Iozzo RV, &, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
43. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
44. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, &, Iozzo RV, (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136, 729-743. (Pubitemid 27083772)
45. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, &, Eichstetter I, (1999) Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96, 3092-3097. (Pubitemid 29148849)
46. Bi X, Pohl NM, Qian Z, Yang GR, Gou Y, Guzman G, Kajdacsy-Balla A, Iozzo RV, &, Yang W, (2012) Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 33, 326-330.
47. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, Iozzo RV, Augenlicht LH, &, Yang W, (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29, 1435-1440.
48. Biaoxue R, Xiguang C, Hua L, Hui M, Shuanying Y, Wei Z, Wenli S, &, Jie D, (2011) Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 26, 9-21.
49. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, &, Iozzo RV, (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173, 844-855.
50. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, &, Edwards IJ, (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 1042-1053.
51. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, &, Iozzo RV, (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 1104-1110. (Pubitemid 40313888)
52. Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Iino T, et al,. (2008) Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 19, 1533-1539.
53. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, &, Watson PH, (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9, 207-214. (Pubitemid 36109735)
54. Reed CC, Gauldie J, &, Iozzo RV, (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 3688-3695. (Pubitemid 34620532)
55. Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, et al,. (2003) In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 17, 464-466.
56. Santra M, Skorski T, Calabretta B, Lattime EC, &, Iozzo RV, (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 92, 7016-7020.
57. Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS, &, Zhang G, (2012) Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther 5, 143-152.
58. Harper JW, Adami GR, Wei N, Keyomarsi K, &, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816. (Pubitemid 23346377)
59. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al,., et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6, 387-400.
60. De Luca A, Santra M, Baldi A, Giordano A, &, Iozzo RV, (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271, 18961-18965. (Pubitemid 26322772)
61. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G, &, Iozzo RV, (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275, 32879-32887.
62. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, et al,. (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4, 369-379. (Pubitemid 40443922)
63. LaRochelle WJ, Jensen RA, Heidaran MA, May-Siroff M, Wang LM, Aaronson SA, &, Pierce JH, (1993) Inhibition of platelet-derived growth factor autocrine growth stimulation by a monoclonal antibody to the human alpha platelet-derived growth factor receptor. Cell Growth Differ 4, 547-553.
64. Sofeu Feugaing DD, Gotte M, &, Viola M, (2013) More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol 9, 1-11.
65. Rydziel S, &, Canalis E, (1996) Expression and growth factor regulation of platelet-derived growth factor B transcripts in primary osteoblast cell cultures. Endocrinology 137, 4115-4119. (Pubitemid 26321854)
66. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, et al,. (2006) A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25, 3170-3185. (Pubitemid 43881558)
67. Finlay GA, Hunter DS, Walker CL, Paulson KE, &, Fanburg BL, (2003) Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. Am J Physiol Cell Physiol 285, C409-C418. (Pubitemid 36917856)
68. Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E, et al,. (2012) Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209, 1611-1627.
69. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, &, Iozzo RV, (2010) Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J Biol Chem 285, 42075-42085.
70. Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, &, Gressner AM, (2005) Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine 31, 349-357. (Pubitemid 41188056)
71. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassler N, Bomble M, Ostendorf T, Floege J, Gressner AM, &, Weiskirchen R, (2008) Platelet-derived growth factor isoform expression in carbon tetrachloride- induced chronic liver injury. Lab Invest 88, 1090-1100.
72. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, Pavao MS, Tzanakakis GN, &, Karamanos NK, (2012) Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 279, 1177-1197.
73. Fthenou E, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK, &, Tzanakakis GN, (2008) Chondroitin sulfate prevents platelet derived growth factor-mediated phosphorylation of PDGF-Rbeta in normal human fibroblasts severely impairing mitogenic responses. J Cell Biochem 103, 1866-1876. (Pubitemid 351501917)
74. Berdiaki A, Zafiropoulos A, Fthenou E, Katonis P, Tsatsakis A, Karamanos NK, &, Tzanakakis GN, (2008) Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. Biochim Biophys Acta 1780, 194-202. (Pubitemid 351162894)
75. Ruhland C, Schonherr E, Robenek H, Hansen U, Iozzo RV, Bruckner P, &, Seidler DG, (2007) The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 274, 4246-4255. (Pubitemid 47228640)
76. Schaefer L, &, Iozzo RV, (2012) Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22, 56-57.
77. Merline R, Iozzo RV, &, Schaefer L, (2012) Small leucine-rich proteoglycans: multifunctional signaling effectors. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos N, ed.), pp. 185-196. De Gruyter, Berlin, Germany.
78. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, &, Iozzo RV, (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 26408-26418. (Pubitemid 44401849)
79. Iozzo RV, &, Karamanos N, (2010) Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 277, 3863.
80. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
81. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, &, Iozzo RV, (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101, 406-412. (Pubitemid 28067338)
82. Yamaguchi Y, &, Ruoslahti E, (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336, 244-246.
83. McBain AL, &, Mann DM, (2001) Purification of recombinant human decorin and its subdomains. Methods Mol Biol 171, 221-229.